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Available online 15 May 2008Virus–host interactions essential for alphavirus pathogenesis are poorly understood. To address this
shortcoming, we coupled retrovirus insertional mutagenesis and a cell survival selection strategy to
generate clonal cell lines broadly resistant to Sindbis virus (SINV) and other alphaviruses. Resistant cells
had signiﬁcantly impaired SINV production relative to wild-type (WT) cells, although virus binding and
fusion events were similar in both sets of cells. Analysis of the retroviral integration sites identiﬁed the
neuroﬁbromin 1 (NF1) gene as disrupted in alphavirus-resistant cell lines. Subsequent analysis indicated
that expression of NF1 was signiﬁcantly reduced in alphavirus-resistant cells. Importantly, independent
down-regulation of NF1 expression in WT HEK 293 cells decreased virus production and increased cell
viability during SINV infection, relative to infected WT cells. Additionally, we observed hyperactive RAS
signalling in the resistant HEK 293 cells, which was anticipated because NF1 is a negative regulator of
RAS. Expression of constitutively active RAS (HRAS-G12V) in a WT HEK 293 cell line resulted in a marked
delay in virus production, compared with infected cells transfected with parental plasmid or dominant-
negative RAS (HRAS-S17N). This work highlights novel host cell determinants required for alphavirus
pathogenesis and suggests that RAS signalling may play an important role in neuronal susceptibility to
SINV infection.
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Alphaviruses are arthropod-borne, enveloped, positive sense,
single stranded RNA viruses in the Togaviridae family. The Alphavirus
genus includes potential biological weapons [e.g. Western (WEEV),
Eastern (EEEV), and Venezuelan equine encephalitis viruses (VEEV)]
and public health threats [e.g. Chikungunya, Sindbis, Ross River (RRV),
and Barmah Forest viruses]. Although aspects of alphavirus assembly,
RNA replication, virus binding, and entry have been studied (Strauss
and Strauss, 1994), no licensed human vaccine or effective therapeu-
tics are available to combat alphavirus infection (Nagata et al., 2005;
Paessler et al., 2006; Phillpotts et al., 2005; Reed et al., 2005; Rulli
et al., 2005; Schoepp et al., 2002). Elucidating virus–host interactionssova), aaron.domina@enc.edu
davey@utmb.edu (R.A. Davey),
.edu (S.J. Watowich).
n Nazarene College, Quincy,
l rights reserved.essential for alphavirus pathogenesis should provide insights to help
develop novel therapeutics and treatments.
Alphavirus-resistant clonal cell lines were generated from virus-
susceptible cells using a combination of insertional mutagenesis and
virus selection. A similar approach was previously utilized to identify
cellular determinants of susceptibility to SINV infection (Jan et al.,
1999). In that study, Chinese hamster ovary (CHO) cells mutagenized
by retroviral insertion were selected for survival following infection
with SINV. However, only partially virus-resistant clones were
generated, of which the most resistant cell line was shown to lack
surface heparan sulfates leading to inefﬁcient SINV cell binding and
delayed virus replication. Unfortunately, the cellular gene disrupted
by the retroviral integration event was not identiﬁed (Jan et al., 1999).
Extensive human bioinformatics databases may facilitate the
identiﬁcation of potential host cell factors and pathways that promote
virus resistance. To take advantage of these databases, the well-
characterized human HEK 293 cell line was chosen for this study.
Although isolated from embryonic kidney cell culture, this cell line
supports replication of diverse viruses and is closely related to
differentiating neurons (Graham et al., 1977), a property that may
Fig. 1. Characterization of alphavirus-resistant clone 9. (A) Detection of SINV genome in
cells. Total RNA was prepared and used for RT-PCR with primers speciﬁc for
ampliﬁcation of a 638 nucleotide portion of the SINV nsP4 (polymerase) gene, which
is required for genome replication. (B, C) Cross-virus resistance of clone 9. The data
shown is representative of 2 or more independent experiments. Surviving cells were
ﬁxed with 10% formaldehyde and stained with crystal violet. (B) WT HEK 293 cells and
clone 9were infectedwith SINV-TE at anMOI of 0.1 PFU/cell or HJV at anMOI of 0.5 PFU/
cell. Cells were ﬁxed and stained on day 3 post-infection. (C) WT HEK 293 cells and
clone 9 were treated with IFN-α (200 U/ml) one day before RRV was added at an MOI of
0.1 PFU/cell. Cells were ﬁxed and stained on day 5 post-infection. (D) Production of
progeny virus by clonal cell line 9. Clone 9 and WT HEK 293 cells were infected with
SINV-83-GFP at an MOI of 0.1 PFU/cell. At the times indicated, supernatants were
removed and titrated onto HEK 293 cells. The data shown is the mean±SD from 3
independent experiments.
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induced neurological disease.
Retrovirus-based insertional mutagenesis can result in either
diminished or increased gene expression, gene truncation, or altered
gene processing (Uren et al., 2005). Modiﬁed gene expression in host
cells may disrupt virus–host interactions required for virus cyto-
pathogenicity, or stimulate host cell responses that protect against
cytopathogenicity. In either case, mutagenized cells that are resistant
to challenge with a cytotoxic pathogen could be used to identify host
factors that provide protection from pathogen-induced cytotoxicity.
Sindbis-83 virus (SINV-83), a chimeric virus encoding the structural
proteins of VEEV attenuated strain TC-83 and the non-structural
proteins of SINV (Paessler et al., 2003), was chosen for pathogen
challenge to maximize laboratory safety. This virus is safely handled
under BSL-2 laboratory conditions, yet is closely related to pathogenic
encephalitic alphaviruses and highly cytopathic in cell culture
(Paessler et al., 2003). SINV has been the archetypal alphavirus for
studying neurovirulence due to it ability to cause encephalomyelitis in
young mice (Grifﬁn, 2005). The utilization of chimeric SINV-83 may
improve understanding of neurovirulence if the selected SINV-83-
resistant cells arise from changes in host cell factors that interact with
the SINV non-structural proteins.
Results
Generation of alphavirus-resistant cells
Retroviral insertional mutagenesis and SINV-83 challenge were
used to generate clonal populations of SINV-resistant cells. A
homogeneous population of HEK 293 cells, susceptible to alpha-
virus-induced cytolysis, was modiﬁed by infection (MOI of 5 PFU/cell)
with replication incompetent retrovirus encoding enhanced green
ﬂuorescent protein (EGFP). Approximately 108 modiﬁed cells, each
containing discrete genome disruptions through retroviral insertion,
and 108 unmodiﬁed control cells (WT HEK 293) were separately
challenged (MOI of 0.1 PFU/cell) with SINV-83. Approximately 100
colonies of retrovirus modiﬁed cells survived SINV-83 challenge, and
were isolated and cloned. Signiﬁcantly, no resistant colonies were
recovered from WT HEK 293 control cells infected with SINV-83.
Retrovirus transduction of cells resulted in SINV-83 resistance at a
frequency of 10−6. A subset of the resistant colonies was cloned and
characterized in detail as described below.
The possibility that surviving clonal cells harboured infectious
virus was investigated. Most supernatants tested from clonal cells
harboured very low levels of virus, with titers typically b103–104 PFU/
ml. However, when supernatants from these clonal cells were added
toWT HEK 293 cells, theWTcells showed CPE and produced one-step
virus growth curves similar to those produced when infected with
SINV-83 (data not shown). These results indicated that the virus
ampliﬁed within the selected clonal cells was not attenuated. To
further characterize the resistant clonal cells, each was cured of
infection by transient treatment with interferon alpha (IFN-α), which
stimulates an antiviral response against RNA viruses, including
alphaviruses (Weber et al., 2004). This treatment effectively elimi-
nated virus from 25 of 27 tested clonal cells lines; the culture
supernatant from treated resistant cells no longer caused cytopathic
effects (CPE) when added to WT HEK cells (data not shown).
To determine if the IFN-α-treated cells were still resistant to virus
challenge, they were re-challengedwith SINV-83 at anMOI of 0.1 PFU/
cell and CPE kinetics were monitored. The IFN-α-treated cells
remained resistant to virus challenge. Sixteen clones had signiﬁcantly
delayed CPE, which occurred between 3 and 6 days post-infection
compared to day 3 in control, WT cells. Nine clones survived virus
challenge with little or no apparent CPE. Eight of the 9 completely
resistant clones had morphological changes or grew slowly. However,
one clone (termed clone 9) displayed nearWTcell growth kinetics andmorphology, and was chosen for more extensive analysis as discussed
below.
Clone 9 did not contain SINV genomes
It was possible that clone 9 contained an attenuated non-
cytopathic SINV genome that might have interfered with replication
of WT SINV through a “super-infection exclusion” or “defective-
interfering” mechanism (Tsiang et al., 1988). RT-PCR was performed
using RNA isolated from resistant clones and WT cells to detect the
portion of the SINV genome encoding the nsP4 RNA polymerase,
which is necessary for viral RNA replication and does not readily
tolerate mutations. No PCR product was detected from clone 9 or WT
cells (Fig. 1A). In contrast, clone 26, which was the only clone per-
sistently infected with an attenuated mutated SINV virus (data not
shown) and used as a positive control, generated a PCR product of the
expected size (638 base pairs). The PCR product from clone 26 remained
clearly visible after a 125-fold dilution of the initial RNA sample (data
not shown), implying that even low levels of SINV virus were not
present in clone 9. Western blotting of clone 9, using antibodies against
SINV proteins, was negative for the presence of SINV antigens (data not
shown). These results demonstrated that clone 9 was unlikely to
harbour defective-interfering or attenuated virus.
Clone 9 resisted diverse alphaviruses
Clone 9 was challenged with different alphaviruses to determine if
the protective phenotype was speciﬁc for SINV-83 or involved a more
general antiviral mechanism. Representative alphaviruses from four
different lineages (Strauss and Strauss, 1994) were used to challenge
resistant clone 9. No CPE was observed in clone 9 following infection
with Highlands J virus (HJV; recombinant WEE complex) or with
SINV-TE (SIN lineage; Fig. 1B, Table 1). In contrast, clone 9 did not
Table 2
Retroviral integration sites identiﬁed in clone 9
IPCR
fragment
Targeted genea GenBank
accession #
Proviral integration
and orientation
1 No hit/Ras-related GTP binding
C (RRAGC)
NM_022157 23 kb downstream, OTOb
2 Neuroﬁbromin 1 (nf1) NM_000267 1st intron, OTOb
3 LSM12 homolog (S. cerevisiae)
(lsm12)
NM_152344 1st intron, OTOb
4 Ubiquitin-conjugating enzyme
E2M (ube2m)
NM_003969 1st intron, OTOb
a Candidate gene identiﬁcations are based on proximity to the retroviral integration
site.
b opposite transcriptional orientation.
Table 1
Characterization of the virus-resistant phenotype observed in clone 9
Virus (MOI [PFU/cell]) Cell survival (%)
WT Clone 9
SINV-83 (0.1) b10 N80
SINV-TE (0.1) b10 N80
HJV (0.5) b10 N80
RRV (0.1) b10 b10
RRV+IFN-α (0.1) b10 N80
TC-83 (0.1) b10 b10
TC-83+IFN-α (0.1) b10 40-80
WNV (0.1) b10 b10
WNV+IFN-α (0.1) b10 b10
Cell survival was analyzed on 3 days post-infection for SINV-83, SINV-TE, HJV, andWNV
challenges, 4 days post-infection for VEEV TC-83 challenge, and 5 days post-infection
for RRV challenge.
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[Semliki Forest complex]. In these cases, CPE kinetics were similar to
those observed in control challenge experiments using WT HEK 293
cells (Table 1). In addition, WT HEK 293 and clone 9 cells showed
similar CPE responses when challenged with West Nile ﬂavivirus
(WNV; Table 1).
IFN treatment results in a transient antiviral state in numerous cell
types, making them temporarily resistant to infection by many RNA
viruses (Weber et al., 2004). We examined if sub-protective doses of
IFN-α (20 U/ml IFN-α) could synergistically protect clone 9 against the
above tested viruses. WT HEK 293 cells challenged with VEEV TC-83,
RRV, or WNV, and concurrently treated with sub-protective doses of
IFN-α showed complete CPE (Table 1). In contrast, clone 9 showed no
CPE when challenged with RRV following treatment with sub-
protective doses of IFN-α (Fig. 1C, Table 1). Clone 9 challenged with
VEEV TC-83 following treatment with sub-protective doses of IFN-α
showed a clear reduction in CPE relative to WT cells (Table 1). Clone
9 challenged with WNV following treatment with sub-protective
doses of IFN-α showed extensive CPE, similar to WT cells. As an
additional control, WT cells that were repeatedly treated with 200 U/
ml of IFN-α at 13 day intervals and then challenged with VEEV TC-83
or RRV showed complete CPE; this result indicated that IFN-induced
protection was not due to the initial “curing” procedure (data not
shown).
Clone 9 exhibited impaired SINV-83 production
We next determined whether clone 9 survived viral challenge
through a mechanism that impaired virus production. Cells were
infected with recombinant SINV-83 encoding GFP (Dr. Ilya Frolov,
UTMB) at an MOI of 0.1 PFU/cell. GFP expression in infected cells
provided a marker to efﬁciently monitor virus titer. Following infec-
tion of WTcells, virus titers rose to ∼105 foci/ml at 36 h, and reached a
peak of 3×105 foci/ml at 48 h. After 48 h, virus titers decreased,
coinciding with extensive CPE in the infected WT cells (Fig. 1D). In
contrast, infected clone 9 cells produced titers of ∼3×102 foci/ml
throughout the experiment, with little or no CPE observed. Thus, the
resistant cells could be infected with SINV-83, but had signiﬁcant
deﬁciencies in virus production.
Analysis of retroviral integration sites
To identify host cell factors responsible for the antiviral phenotype,
we analyzed sites of retroviral integration within the genome of clone
9. The resistant cells likely received several independent integration
events due to the high MOI used during retroviral insertional
mutagenesis. By means of inverse PCR (IPCR), four provirus insertion
site sequences (labelled IPCR sites 1–4) were separately recovered and
sequenced from clone 9. As expected, each provirus sequencecontained the EGFP transgene. Homology BLAST searches (Altschul
et al., 1990, 1997) were performed to identify genes that surrounded
the four integration sites (Table 2). No functional genes were identiﬁed
within the immediate vicinity of IPCR site 1. However, IPCR site 1 was
23 kb downstream of the rragc gene. IPCR sites 2, 3 and 4 were located
within the ﬁrst intron of the nf1, lsm12, and ube2m genes, respectively.
All retrovirus integrations were found in the opposite transcriptional
orientation (OTO) relative to the disrupted host genes.
Nf1, ube2m and lsm12 mRNA levels were reduced in resistant clone 9
Retroviral integration can alter host gene sequences and/or their
expression levels (Trono, 2003; Uren et al., 2005). Real-time RT-PCR
was performed to determine whether provirus insertions affected
RNA transcript levels from the rragc, nf1, lsm12, and ube2m genes in
clone 9 relative to unmodiﬁed WT HEK 293 cells. Expression levels
were normalized relative to gapd gene expression, and these normal-
ized gene expression levels compared between the resistant and WT
HEK 293 cells. Retrovirus integrations within the ﬁrst intron of the nf1,
ube2m, or lsm12 genes resulted in a signiﬁcant reduction of their RNA
levels in clone 9 compared to WT HEK 293 cells (Fig. 2A). Normalized
ube2m, lsm12, and nf1 RNA levels were reduced 47%, 49%, and 30% in
the resistant clone relative to WT cells, respectively. There was no
signiﬁcant difference in rragc RNA levels in the resistant clone andWT
cells, suggesting that the integrated provirus did not affect rragc gene
expression or stability.
NF1 and UBE2M protein levels were reduced in resistant cells
Although quantitative RT-PCR showed that nf1, lsm12, and ube2n
RNA expression was reduced in clone 9 relative to WT cells, Western
blotting was used to determine if the corresponding protein
expression levels were affected. Unfortunately, no speciﬁc anti-
RRAGC and anti-LSM12 antibodies were available, restricting this
analysis to NF1 and UBE2M proteins. NF1 and UBE2M protein
expression levels were reduced in clone 9 compared to WT HEK 293
cells (Fig. 2B). In clone 9, a truncated UBE2M protein was detected
using antibody that recognized UBE2M C-terminal residues 169–180.
No truncated UBE2M proteinwas detected with anti-UBE2M antibody
speciﬁc for residues 11–26 in clone 9 (Fig. 2B). These observations
suggested that retroviral integration resulted in expression of an N-
terminal truncated UBE2M protein.
Truncated nf1 and ube2m transcripts were produced in virus-resistant
cells
Retroviral integration can alter gene transcription by insertion of a
viral promoter within a gene or stimulation of cryptic/alternative
cellular promoters via enhancer elements located in retrovirus long
terminal repeats (LTR) (Trono, 2003), often producing non-functional
or rapidly degraded proteins. To determine if truncated gene products
Fig. 2. Characterization of retroviral mutagenesis gene disruption in alphavirus-resistant clone 9. (A) Real-time RT-PCR analysis was performed by using total RNA derived from WT
HEK 293 cells and clone 9 with primers speciﬁc to ube2m, nf1, lsm12 and rragc transcripts. Gene-speciﬁc transcript amounts were normalized to gapd levels. The data shown is the
mean±SD from 2 independent experiments. ⁎⁎ indicates P≤0.001 and ⁎ indicates P≤0.05 compared toWT control. (B) Western blotting analysis of protein lysates fromWT HEK 293
cells and clone 9 usingα-UBE2M C-terminus,α-UBE2M N-terminus, andα-NF1 antibodies. Anti-beta-actin (α-ACTB) antibody was used to verify protein loading. Arrow indicates N-
terminally truncated UBE2 protein. (C) Characterization of truncated transcripts in alphavirus-resistant clone 9. Analysis of the 5′ end of truncated ube2m and nf1 transcripts by 5′
RLM-RACE. Diagram of ube2m and nf1 gene structures and products identiﬁed in clone 9. Hatched boxes represent untranslated regions of the gene. Introns are not drawn to scale.
Horizontal arrows show PCR products generated with gene-speciﬁc primers; vertical arrows indicate sites of provirus integration.
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performed to determine the nucleotide sequence at the 5′ end of
nf1, ube2m and lsm12 transcripts.
5′ RLM-RACE with primers speciﬁc for nf1 RNA transcripts resulted
in products that coded for full-length protein in both the parental HEK
293 cells and in clone 9. Additionally, clone 9 contained a truncated nf1
RNA transcript (Fig. 2C). The transcript from clone 9 contained 13
nucleotides of nf1 intron sequence located upstream of exon 3, spliced
to exon 3 utilizing a cryptic splice donor site in the intron (Fig. 2C). It is
likely that provirus integration in clone 9 resulted in LTR enhancer
activation of cryptic promoters within nf1 intron/exon sequences
upstream of exon 3, thus yielding truncated nf1 transcripts. Sequence
analysis showed that the truncated transcripts in clone 9 could encode
NF1 proteins lacking 68 N-terminal amino acids. Since the NF1 protein
contains 2818 amino acids (327 kDa) (Gutmann et al., 1991), this N-
terminal truncationwouldmigrate similarly to full-length NF1 protein
using SDS polyacrylamide gel electrophoresis. Mutations that result in
deletion of nf1 exons 1 and 2 have been reported among neuroﬁ-
bromatosis type I patients (Ars et al., 2003; Fahsold et al., 2000;
Spurlock et al., 2007; Wimmer et al., 2006), suggesting that such a
truncation would compromise protein function.
5′ RLM-RACEwith primers speciﬁc for ube2m transcripts identiﬁed
RNA products sufﬁcient to encode full-length UBE2M protein in WT
HEK 293 and resistant cells. However, the resistant cells additionally
encoded two RNA products with 5′ deletions (Fig. 2C). The 5′ end of
the ﬁrst truncated ube2m product contained three adenine nucleo-
tides preceding exon 2, which might have occurred from incompleteremoval of cap structure during 5′ RLM-RACE (Fig. 2C). The 5′ end of
the second truncated ube2m product contained a nucleotide sequence
corresponding to the ube2m second intron preceding exon 3 (Fig. 2C).
These results suggest that the integrated provirus activated cryptic
promoters within the intronic ube2m sequence upstream of exons 2–
3, thus yielding truncated transcripts. The ﬁrst in-frame ATG codon
appears at the +188 and +90 positions for the ﬁrst and second
truncated products, respectively, and several out-of-frame ATG
triplets occur upstream of the in-frame ATG codons (Fig. 2C). The
smaller 17 kDa UBE2M antibody-reactive protein observed in virus-
resistant clones suggests an alternative initiation of translation at non-
ATG codons, since the predicted molecular weight for a protein
initiated from the ﬁrst in-frame ATG triplet is 10.1 kDa. CTG coding for
leucine represents the most common alternative translation initiation
codon for mammalian mRNA (Touriol et al., 2003). The ﬁrst in-frame
CTG codon occurs at the +15 position of the ﬁrst truncated product
(Fig. 2C), and could encode an N-terminally truncated UBE2M protein
with a predicted molecular weight of 16.5 kDa, consistent with the
observed truncated UBE2M protein.
The N-terminally truncated UBE2M protein observed in the
resistant cells was likely non-functional. A 12 to 26-residue extension
(called docking peptide) at the N-terminus of UBE2M selectively
recruits NEDD8 E1 (APPBP1–UBA3 complex) to promote thioester
formation between UBE2M and NEDD8 (Huang et al., 2004). Deleting
the UBE2M docking peptide substantially reduces UBE2M binding to
E1, and impairs the transfer of NEDD8 to substrates of the NEDD8
modiﬁcation system (Huang et al., 2004).
Fig. 3. Effect of siRNA-mediated down-regulation of NF1 expression inWTHEK 293 cells
on SINV-83-GFP production and cellular viability. (A) Down-regulation of NF1 protein
expression. Western blot analysis of protein lysates from WT HEK 293 cells transiently
transfected with NF1-speciﬁc siRNA compared with non-targeting control siRNA
(siCONTROL), mock-transfected cells (Mock) and non-transfected cells (NT). Cell lysates
were tested 2–5 days after transfection usingα-NF1 antibody. Anti-beta-actin (α-ACTB)
antibody was used to verify protein loading. (B, C) WT HEK 293 cells transiently
transfected with NF1-speciﬁc siRNA were infected 2 days after transfection with SINV-
83-GFP, MOI of 0.1 PFU/cell. The data shown is themean±SD of triplicate cultures that is
representative of 3 separate experiments. (B) Production of SINV-83-GFP by transfected
cells. At the times indicated, supernatantswere removed and titrated ontoHEK 293 cells.
** indicates P≤0.05 and * indicates P≤0.1 compared to siCONTROL. (C) Cell viability was
assessed 5 days post infection using an MTT-based assay.
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resulted in products that coded for full-length protein in both the
virus-resistant clone and WT HEK 293 cells; truncated RNA products
were not detected (data not shown).
siRNA-mediated NF1 down-regulation inhibited SINV-83 production and
prolonged HEK 293 cell survival
To investigate the cellular mechanism(s) responsible for the
resistant phenotype, siRNA targeting was used to selectively down-
regulate host gene expression in WT cells. siRNA modiﬁed cells were
challengedwith SINV to determine the impact of selective gene down-
regulation. Real-time RT-PCR showed that rragc gene expression was
similar in clone 9 and WT HEK 293 cells, suggesting that RRAGC was
not involved in protecting cells from alphavirus challenge. siRNA-
mediated down-regulation of lsm12 and ube2m expressions in WT
HEK 293 cells did not delay or reduce SINV-83-GFP production or
SINV-83-GFP-induced CPE (data not shown), suggesting that LSM12
and UBE2M down-regulations did not contribute to the alphavirus-
resistant phenotype.
To determine whether reduced nf1 expression contributed to the
alphavirus-resistant phenotype observed in clone 9, siRNA was used
to down-regulate nf1 expression inWTHEK 293 cells. Following gene-
speciﬁc knockdown, decreased NF1 protein expression inWTHEK 293
cells was conﬁrmed by Western blotting (Fig. 3A). Non-targeting
siRNA andmock transfection had no impact on NF1 protein expression
(Fig. 3A). NF1 protein expression was down-regulated rapidly, with
little protein observed at 2 days post-transfection. NF1 protein levels
remained reduced for at least 5 days post-transfection.
Two days post-transfection, cells were challenged with SINV-83-
GFP at an MOI of 0.1 PFU/cell. To quantify the impact of nf1 down-
regulation on SINV-83-GFP production, virus titers were determined
at different time points post-infection. nf1 down-regulation in WT
HEK 293 cells substantially reduced virus production, resulting in a
36 h lag (Fig. 3B) in virus production relative to infected control cells.
Virus production at 48 and 60 h post-infection in cells transfected
with NF1-targeting siRNAs was also suppressed 10–50-fold relative to
virus production of cells transfected with non-targeting siRNA or
mock transfected. This experiment suggests that NF1, or the protein
networks modulated by NF1, plays an important role in alphavirus
pathogenesis.
Increased cell survival was observed 5 days post-infection for NF1-
down-regulated cells, consistentwith reduced virus production in these
cells. MTT-based analysis of cell viability was performed when CPE was
clearly observed in control cells. Viability measurements were reported
as the percentage of viable cells within the infected sample, with 100%
viability being assigned to the same non-infected transfection (Fig. 3C).
SINV-83-GFP-induced cell death was signiﬁcantly delayed and reduced
in cells transfected with NF1-targeting siRNAs, relative to cells
transfected with either control siRNA or mock transfected (Fig. 3C).
These observations correlated with the reduction in virus production
that was observed in cells with NF1 down-regulation.
Hyperactive RAS activity in NF1-defﬁcient alphavirus-resistant cells
NF1 possesses RAS-speciﬁc GTPase-activating property (GAP) that
accelerates the intrinsic GTPase activity of RAS proteins and promotes
the formation of inactive GDP-bound RAS (Wennerberg et al., 2005).
Thus, NF1 functions as a negative regulator of RAS signalling
(Wennerberg et al., 2005). Reduction of NF1 levels and/or NF1-
speciﬁc GAP activity is commonly associated with hyperactive RAS
signalling, either through elevated levels of active RAS proteins or
normal levels of RAS protein with hypersensitive, exaggerated and
prolonged signalling of active RAS in response to growth factor
stimulation (Lau et al., 2000; Weiss et al., 1999). To determine if
reduced levels of NF1 protein in the alphavirus-resistant clone 9resulted in hyperactive RAS signalling, we measured activated RAS in
whole-cell extracts of serum-starved WT HEK 293 and resistant cells
(Fig. 4A). Using a RAS activation assay, increased basal levels of
activated RAS were measured in the resistant cells relative to WT HEK
293 cells (Fig. 4A). This experiment indicated that hyperactive RAS
signalling was associated with reduced NF1 expression in the
alphavirus-resistant clone 9.
Expression of constitutively active RAS in HEK 293 cells inhibited SINV-
83 production
Since hyperactive RAS signalling was correlated with reduced NF1
expression in alphavirus-resistant cells, we hypothesized that active
RAS signalling may reduce alphavirus replication. To address this
question we examined SINV-83 production in HEK 293 cells expres-
sing a constitutively active RAS. The constitutively active mutant
HRAS-G12V inhibits GTP hydrolysis, thus enabling RAS-G12V to
remain active (Schlichting et al., 1989). As control, the HRAS-S17N
dominant-negative mutant does not exchange bound GDP and
suppresses RAS activity by competing with endogenous cellular RAS
for upstream activators (Feig and Cooper, 1988).
Fig. 4. Hyperactive RAS signalling in alphavirus resistance. (A) Hyperactive RAS
signalling in alphavirus-resistant clone 9. RAS activity in whole-cell extracts from clone
9 andWT HEK 293 cells. Cells were serum-starved for 5 h prior to cell lysis and analysis.
The data shown is the mean±SD from 3 independent experiments. ⁎ indicates P≤0.001
compared toWTcontrol. (B, C) Effect of constitutively active RAS expression on SINV-83
production in WT HEK 293 cells. HEK 293 cells transiently transfected with
constitutively active (G12V) or dominant-negative (S17N) form of pcDNA3.1-HA-
HRAS plasmid, parental plasmid (pcDNA3.1), or mock transfected (Mock). (B) Western
blot analysis of RAS proteins expression 24 h post-transfection using anti-HA antibody
(α-HA). Anti-beta-actin antibody (α-ACTB) was used to verify protein loading. (C)
Production of SINV-83 by transfected cells. Transfected cells were infected 24 h post-
transfectionwith SINV-83, MOI of 0.1 PFU/ml. At the times indicated, supernatants were
removed and titrated onto HEK 293 cells. The data shown is the mean±SD of triplicate
cultures from1 experiment that is representative of 3 separate experiments. ⁎⁎ indicates
P≤0.01 and ⁎ indicates P≤0.05 compared to parental plasmid.
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production,we infectedHEK 293 cells thatwere previously transfected
with constitutively active RAS (HRAS-G12V), dominant-negative RAS
(HRAS-S17N), parental plasmid, or mock transfected. Expressions of
HA-tagged HRAS-G12V andHRAS-S17N proteins in HEK 293 cells were
conﬁrmed by Western blotting using anti-HA antibody (Fig. 4). To
quantify the impact of RAS proteins on SINV-83-GFP production, virus
titers were determined at different time points post-infection. As
shown in Fig. 4C, cells transfected with parental plasmid had levels of
SINV-83 replication that were similar to that observed in mock-
transfected cells. In contrast, cells transfected with HRAS-G12V had
signiﬁcantly reduced SINV-83 replication (Fig. 4C) relative to mock-
transfected cells. Cells transfected with HRAS-S17N had little effect on
SINV-83 replication, similar to that reported previously (Joe et al.,1996). These results indicate that the activated RAS appears to play a
signiﬁcant role in suppressing SINV-83 replication.
Discussion
In this study, alphavirus-resistant HEK 293 cells were generated by
a combination of retrovirus insertional mutagenesis and a cell survival
selection strategy. This screen utilized SINV-83, a chimeric virus
encoding non-structural proteins of SINV and structural proteins of
TC-83, a tissue-culture adapted attenuated VEEV (from the VEE/EEE
lineage) (Paessler et al., 2003). The observed resistant cells may have
resulted from changes to host cell factors that interactedwith the SINV
non-structural proteins, the VEEV TC-83 structural proteins, or both.
One selected cell line, termed clone 9, was resistant to SINV-83, SINV-
TE, HJV and RRV. SIN-TE is a neuroadapted SIN virus (Lustig et al.,
1988). HJV is closely related to WEEV; the glycoproteins of these
viruses are related to those of Sindbis-like viruses, whereas their non-
structural proteins are related to those of EEEV (Weaver et al., 1997).
RRV is a representative of the Semliki Forest complex (Strauss and
Strauss, 1994). Clone 9 was only partially protected from VEEV TC-83.
These results suggest that the resistance phenotype observed in clone
9 results from interference with the SINV non-structural protein
functions. Consistent with this interpretation, both WT HEK 293 cells
and the resistant cells could be equally infected with a murine
leukemia retrovirus pseudotyped with VEEV envelope proteins, as
measured by an established luciferase-based virus entry assay (data
not shown) (Kolokoltsov and Davey, 2004). These later experiments
also suggested that the selected alphavirus-resistant cells had normal
virus binding and fusion properties.
Retroviral preference for distinctive regions within a gene,
governed by the virus-speciﬁc preintegrational complex, has been
previously documented (Wu et al., 2003, 2006). Our observed gene
insertion locations were consistent with the observed preference of
murine leukemia virus to integrate in and around promoters (Trono,
2003). Three (i.e., in the nf1, lsm12, and ube2m genes) of the four
integration events observed in our insertional mutagenesis study
occurred within the ﬁrst intron of a gene. The ∼50% lower RNA
transcript levels of ube2m and lsm12 observed in the virus-resistant
cells relative to WT cells were not unexpected, since HEK 293 cells
were diploid and retroviral integration was monoallelic (i.e., occurred
in only one copy of a chromosome pair).
Primers used for real-time RT-PCR analysis detected both truncated
and full-length nf1 gene transcripts. The ∼30% reduction of nf1 RNA
levels observed in the virus-resistant cells relative to WT cells was
likely due to the presence of both truncated and full-length nf1 RNA in
the virus-resistant cells. The large decrease in NF1 protein levels
observed in virus-resistant cells relative to WT cells suggests that the
truncated nf1 RNAwas either not translated or translated into unstable
NF1 protein products. A non-linear relationship between RNA and
protein expression levels has been well documented (Mehra et al.,
2003). Decreased NF1 protein levels were shown to be functionally
signiﬁcant in humans, since reduced NF1 protein levels and/or N-
terminal deletion mutants were associated with neuroﬁbromatosis
disease. Neuroﬁbromatosis patients heterozygous for nf1 mutations
develop clinical symptoms of the disease (Upadhyaya et al., 2007) and
speciﬁc deletions of nf1 exons 1 or 2 have been reported among
neuroﬁbromatosis type I patients (Ars et al., 2003; Fahsold et al., 2000;
Spurlock et al., 2007; Wimmer et al., 2006). Thus, it is likely that the
NF1 protein down-regulation observed in our virus-resistant cells
could give rise to a unique and functionally signiﬁcant phenotype.
SINV-83 production was signiﬁcantly inhibited when NF1 expres-
sion was transiently down-regulated in WT HEK 293 cells. Moreover,
these modiﬁed cells exhibited resistance to virus-induced cell death.
These results suggest that the characterized NF1-deﬁciency in the
virus-resistant cells was largely responsible for the virus-resistant
phenotype. Additionally, these studies highlight a previously unknown,
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tional pathways) in alphavirus pathogenesis.
NF1 contains several distinct domains, although their functions are
largely unknown. The GAP-related domain of NF1 possesses RAS-
speciﬁc GTPase-activating protein (GAP) activity (Boyanapalli et al.,
2006; Corral et al., 2003; D'Angelo et al., 2006; Martin et al., 1990) that
accelerates the intrinsic GTPase activity of RAS proteins. Thus, NF1 is a
negative regulator of RAS activity (Wennerberg et al., 2005), and NF1
down-regulation is associated with hyperactive RAS activity and
elevated RAS signalling (Lau et al., 2000; Weiss et al., 1999). The
observation that the expression of constitutively active RAS in WT HEK
293 cells inhibited SINV replication was consistent with a role for the
NF1 protein and downstreamRAS signalling in alphavirus pathogenesis.
SINV-83 replication was more inhibited in WT cells that were
modiﬁed by siRNA-mediated NF1 down-regulation compared to WT
cells transfected with constitutively active RAS. This observation could
result from NF1 possessing an unidentiﬁed activity which is required
for alphavirus production, independent from NF1's RAS-speciﬁc
GTPase-activating property. Alternatively, NF1 down-regulation may
affect the activity of several other RAS isoforms (i.e., KRAS4A, KRAS4B,
and NRAS) and their downstream pathways (Yan et al., 1998). These
pathways, which function independently of HRAS, may be addition-
ally involved in alphavirus pathogenesis. Treatment with IFN-α may
have enhanced some hyperactive RAS signalling pathways in the clone
9 cells, thus enabling these treated cells to survive RRV and VEEV TC-
83 challenges. Although IFN-α elicits an antiviral response by
activating components of the MEK/ERK pathway (David et al., 1995;
Lechner and Pfaller, 2001) the detailed interplay between alphavirus
inhibition and RAS signalling remains to be determined.
Conclusions
This work identiﬁed a novel host cell determinant that is involved
in alphavirus pathogenesis and demonstrated the power of a rigorous
cell survival selection screen as a tool to identify host cell components
that impact virus production and virus-induced CPE. Host cell proteins
(and their associated pathways) that protect cells from virus infection
offer novel therapeutic targets and strategies to combat infectious
diseases. Future work will identify in greater detail the NF1 properties
and/or NF1-associated pathways that are responsible for inhibiting
alphavirus production.
Materials and methods
Generation of resistant clones by retroviral insertional mutagenesis
HEK 293 cells were maintained in DMEM containing 4.5 g/l
glucose, 10% (v/v) heat-inactivated FBS (HyClone, Logan, UT) and 1%
(v/v) penicillin/streptomycin. Cell genomes were modiﬁed by inser-
tional mutagenesis using a replication incompetent retrovirus. To
produce recombinant retroviruses encoding enhanced green ﬂuor-
escent protein (EGFP), HEK 293 cells were cotransfected with 3
separate plasmids: pGag-Pol (Dr. J Cunningham, Harvard Medical
School) encoding Gag-Pol proteins of murine leukemia virus, pHCMV-
VSV-G plasmid (Clontech, Mountain View, CA) pseudotyping retro-
viruses with the vesicular stomatitis virus (VSV) G envelope protein,
and pFB-EGFP Moloney murine leukemia-based retroviral vector for
reporter gene delivery and expression. pFB-EGFP was prepared by
cloning the EGFP sequence (Clontech, Mountain View, CA) into the
EcoRI and NotI restriction endonuclease sites of the pFB plasmid
(Stratagene, La Jolla, CA). One day post-transfection, cells were rinsed
and fresh media was added. Two days post-transfection, retrovirus-
containing media was collected, ﬁltered (0.45 μM) and stored at
−80 °C.
Retroviruses encoding EGFPwere used to infect ∼108 HEK 293 cells
at a multiplicity of infection (MOI) of 5 PFU/cell. Two days post-infection, N95% of cells expressed EGFP, as determined by ﬂuorescence
microscopy. Cells were split and the next day challengedwith SINV-83
virus at an MOI of 0.1 PFU/cell. As control, ∼108 of WT HEK 293 cells
were independently challenged with SINV-83, and maintained under
identical conditions as the retrovirus-treated cells. Cell media was
changed daily for the next 5 days. Seven days post-challenge surviving
colonies were isolated and cloned.
SIN-83 persistent virus infection of the surviving clones was
eliminated by treatment with human IFN-α2b (Schering-Plough,
Kenilworth, NJ) at a dosage of 200 U/ml for 3 days. After cultivation for
an additional 10 days in the absence of IFN-α, resistant cells were
tested for residual virus by inoculating WT HEK 293 cells with
surviving clone supernatants and monitoring CPE for 5 days.
PCR for viral genome detection
Total RNAwas isolated by RNaqueous kit (Ambion, Austin, TX) and
its quality and concentration were determined by agarose gel
electrophoresis and UV spectrophotometry. Ten micrograms of RNA
was mixed with 100 pmol of primer (5′-CCACCTCGAGTTTACCCAACT-
TAAACAGCC-3′) located 600 base pairs downstream of the PCR target
in 9 μl of water, heated at 70 °C for 10 min, and then transferred to ice.
Of this mixture, 2 μl was used to synthesize cDNA using Superscript II
(Invitrogen, Carlsbad, CA) and a 1 h incubation at 45 °C. The SINV nsP4
gene (polymerase) was ampliﬁed from cDNA with Taq polymerase
(Sigma-Aldrich, St. Louis, MO), primers 5′-CCACGAGCTCGACCTTG-
GAGCGCAATGTCC-3′ and 5′-CCACCTCGAGGAACTCCTCCCAA-
TACTCGTC-3′, and 30 cycles of PCR (94 °C for 30 s, 55 °C for 30 s,
and 70 °C for 1min). PCR products were separated on 1.5% agarose gels
and visualized with ethidium bromide.
Challenging resistant clonal cell lines with heterologous viruses
SINV-83, SINV-TE and SINV-83-GFP were kindly provided by Dr. I.
Frolov (UTMB). VEEV strains TC-83, HJV, RRV, and WNV were
generously provided by the World Arbovirus Reference Center (Dr.
R. Tesh, UTMB).
Virus was added to cells cultivated to greater than 50% conﬂuence
(Table 1). Cells pretreated with IFN-α at 200 U/ml were challenged the
following day. After signiﬁcant CPE was observed in WT HEK 293 cells
(typically 3–5 days post-alphavirus infection), cells were ﬁxed with 10%
formaldehyde and stained with crystal violet to view residual attached
cells. Virus titers were determined for SINV-83-GFP infection. Cells were
infected at an MOI of 0.1 PFU/cell, and media was collected at indicated
times post-infection, and diluted onto HEK 293 cells. Following 3 h
incubation, cells were overlaid with MEM containing 0.6% gum
tragacanth (w/v), 1% FBS (v/v), and 18 h post-infection foci of infection
containing GFP expressing cells were counted using a UV microscope.
Inverse PCR
Genomic DNA (5 μg) was puriﬁed using GenElute Mammalian
Genomic DNA Miniprep Kit (Sigma-Aldrich, St. Loius, MO) and
digested with BamHI in a total volume of 200 μl for 7 h. Reactions
were puriﬁed by DNA Clean and Concentrator-5 (Zymo Research,
Orange, CA). Digested DNA was self-circularized using T4 DNA ligase
(1200 U; New England BioLabs, Ipswich, MA) and 5% PEG 8000 (w/v)
in a total volume of 500 μl at 16 °C for 16 h. Circular DNA was puriﬁed
by DNA Clean and Concentrator-20 (Zymo Research, Orange, CA) and
used in the primary PCR in a 50 μl reaction volume containing forward
and reverse primers (10 pmol each), PreMix 7 and enzymemix (2.5 U)
in the MasterAmp Extra-Long PCR Kit (Epicentre, Madison, WI). The
thermocycler was programmed for 94 °C for 2 min, followed by
30 cycles of 94 °C for 1 min, 50 °C for 1 min, 72 °C for 5 min and a ﬁnal
extension step at 72 °C for 10 min. The primary PCR product (5 μl) was
used as the template in a secondary PCR reaction using the same
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52 °C. The secondary PCR product was separated on a 1% agarose gel,
puriﬁed and directly sequenced. Sequences ﬂanking the provirus DNA
were BLAST-searched against human genome sequence databases.
The following primers were used in the primary PCR reactions: pFB-
2149-70-For (5′-CAGAAAAAGGGGGGAATAAAG-3′) and pFB-Rev (5′-GGAGAC-
TAAATAAAATCTTTTAT CGAAC-3′). The secondary PCR primers were: pFB-
2665-89-For (5′-CCTCTTGCAGTTGCATCCGA CTTGT-3′) and pFB-Rev.
Real-time RT-PCR
DNase-treated RNA was prepared from 70% conﬂuent cells using
RNeasy Mini Kit (Qiagen, Valencia, CA) following protocols adapted
from the manufacturer's instructions. cDNA was synthesized with
ReactionReady™ First Strand cDNA Synthesis Kit (Super Array,
Frederick, MD).
To determine if residual DNAwere present, control reactions using
pooled RNA from all samples were performed with no reverse
transcriptase added. A no-template control reaction was also run in
parallel with all ampliﬁcations to detect contaminating DNA or the
formation of secondary products generated by primer interactions. To
control for variation in input RNA quantities and reverse transcription
efﬁciencies, reactions were normalized to the glyceraldehyde 3-
phosphatedehydrogenase (gapd) housekeeping gene. Real-time PCR
master mixes were prepared to the ﬁnal concentrations of 200 nM
primers, and iQ SYBR Green Supermix (Bio-Rad, Hercules, CA).
Standard curves were generated for each primer pair using two-fold
serial dilution of cDNAs pooled from WT HEK 293.
Real-time PCR was performed on iCycler iQ thermal cycler (Bio-
Rad, Hercules, CA) using the following protocol: initial denaturation
(1 min 30 s at 95 °C); PCR ampliﬁcation and quantiﬁcation cycle
repeated 50 times (30 s at 95 °C; 30 s at 55 °C; and 30 s at 72 °C with a
single ﬂuorescence measurement); and a melt curve analysis (55–
95 °C) using a heating rate of 0.2 °C per 10 s with continuous
ﬂuorescence measurement.
The PCR “Base Line Subtracted” mode with manual threshold
assignment equal to 300 was used to determine the geometric mean of
the threshold cycle (Ct) using iCycler iQ software (version 3.0a, Bio-Rad,
Hercules, CA). The relative concentration of gene-speciﬁc template in
each sample was determined using the appropriate Ct values and the
standard curve, normalized relative to the gapd reference gene, and
compared to normalized expression levels of the same gene in the
appropriate control sample. To establish the statistical signiﬁcance of
each comparison, two-tailed Student's t-tests assuming unequal
variance were performed.
Primers for lsm12, nf1 and gapd gene transcripts were designed and
produced by SuperArray Bioscience Corp., Frederick, MD (Gene
Symbol: LSM12, SuperArray Cat #: PPH17720A, Reference posi-
tion:392–412; Gene Symbol: NF1, SuperArray Cat #: PPH02089A,
Reference position:1455–1475; Gene Symbol: GAPD, SuperArray Cat
#: PPH00150A, Reference position:362–380). Primers for UBE2M and
RRAGC gene transcripts were designed from reference mRNA
sequences obtained through GenBank (see Table 2 for GenBank
accession numbers) using Primer 3 software (MIT/Whitehead Insti-
tute; http://wwwgenome.wi.mit.edu). The following primers were
used for UBE2M transcript quantiﬁcation (UBE2M-5′, 5′-ACGTCTGCCT-
CAACATCCTC-3′ and UBE2M-3′, 5′-TCCTTGTTCAGTGGGTCCTC-3′) and
for RRAGC transcript quantiﬁcation (RRAGC-5′, 5′-AATTTTTGG-
CACTGGTCTGC-3′ and RRAGC-3′, 5′-CACACCCACCTCAAAAACCT-3′).
Western blotting
Immunoblotting was carried out as previously described (Zou
et al., 2004). Antibody incubation and detection was carried out
following the protocol for ECL Plus Western Blotting Detection
Reagents (Amersham Biosciences, Piscataway, NJ). Primary antibodieswere rabbit polyclonal antibody against the C-terminal epitope
(residues 2760–2818) of the NF1 protein (antibody BL956, Bethyl
Laboratories, Montgomery, TX) and rabbit polyclonal antibodies
against N-terminal (residues 11–26) and C-terminal (residues 169–
180) epitopes of the UBE2Mprotein (antibodies AP2169a, Abgent, San-
Diego, CA and 600-401-865, Rockland, Gilbertsville, PA). The second-
ary antibodywas a horseradish peroxidase (HRP)-conjugated antibody
(donkey anti-rabbit IgG, Amersham Biosciences, Piscataway, NJ).
Loading control primary antibody was mouse polyclonal antibodies
against beta-actin (antibody ab6276, Abcam, Cambridge, MA). The
secondary antibody was a HRP-conjugated antibody (donkey anti-
mouse IgG, Amersham Biosciences, Piscataway, NJ).
5′ RNA ligase-mediated rapid ampliﬁcation of cDNA ends (5′ RLM-RACE)
Total RNA was isolated from 70% conﬂuent cells, as described for
real-time RT-PCR. cDNA containing 5′ RACE Adapters were synthe-
sized according to the manufacturer's instructions (FirstChoice RLM-
RACE, Amibon). Outer 5′ RLM-RACE PCRwas performedwith 2 μl of RT
product. The thermocycler was programmed for 94 °C for 3 min,
followed by 40 cycles of 94 °C for 30 s, 60 °C for 30 s, 72 °C for 1 min
and a ﬁnal extension step at 72 °C for 7 min. 2 μl of Outer 5′ RLM-RACE
PCR product was used in Inner 5′ RLM-RACE PCR using the same
conditions except the annealing temperature was increased to 63 °C.
The secondary PCR product was separated on a 1% agarose gel,
puriﬁed, and directly sequenced. Sequences were BLAST-searched
against human genome sequence databases.
Primers for ube2m and nf1 gene transcripts were designed from
reference mRNA sequences obtained through GenBank (see Table 2. for
GenBank accession numbers) using Primer 3 software (MIT/Whitehead
Institute; http://wwwgenome.wi.mit.edu). Outer 5′ RLM-RACE PCRwas
performed with gene-speciﬁc primers UBE2M-1307–1327-R (5′-
GCCGACCTTAATCACATGGT-3′), NF1-936–956-R (5′-CTTTTCTGCACATT-
CAGCCA-3′) and LSM12-477–497-R (5′-TCCACTTGATATGGGGGTGT-3′).
Inner 5′ RLM-RACE PCR was performed with gene-speciﬁc primers
LSM12-477–497-R, UBE2M-931–951-R (5′-CTGGCTTCCAGTCCTCTCTG-
3′) and NF1-785–805-R (5′-GCTGTTTCCTTCAGGAGTCG-3′).
Transient transfection of siRNA into HEK 293 cells
Silencer™ Fireﬂy Luciferase (GL2+GL3) siRNA (Ambion, Austin, TX)
and siCONTROL Non-Targeting siRNA #2 (Dharmacon, Inc., Lafayette,
CO) targeting Fireﬂy Luciferasewere used independently to determine
optimal conditions for siRNA transfection, including siRNA titration,
using HEK 293 cells infected with replication defective retrovirus
expressing Fireﬂy Luciferase (R. Davey, UTMB). Fireﬂy Luciferase
protein knockdownwas assayed by Luciferase Assay System, Promega,
Madison, WI (data not shown). In addition, siCONTROL Non-Targeting
siRNA #2, having no perfect matches to known human genes, was
used as a negative control.
Transfection procedureswere carried out according to themanufac-
ture's instructions (“Transfecting Stealth RNAi or siRNA into HEK 293
Cells Using Lipofectamine2000,” Invitrogen, Carlsbad, CA). Brieﬂy, 24 h
before transfection, 5×104 HEK 293 cells were seeded in each well of a
24-well plate inMEM-Eaglemedia containing 2mMglutamine, 0.1mM
MEMnon-essential amino acids, 1mM sodium pyruvate,1.5 g/l sodium
bicarbonate, and 10% heat-inactivated FBS (v/v). Transfections were
carried out in triplicate using 2 μl of Lipofectamine2000 reagent and
50 pmol of siRNA per well.
siRNA targeting NF1 transcript (siNF1-D; sense sequence 5′-
AAACGAUGCUGGUCAAACAtt-3′) was designed from reference mRNA
sequences obtained through GenBank (see Table 2 for GenBank
accession numbers) using Dharmacon siDESIGN™ Center software
(http://www.dharmacon.com/sidesign/) and custom synthesized by
Dharmacon Inc. (Lafayette, CO). In addition, Silencer Pre-designed
siRNA named siNF1-A (siRNA ID #121252; sense sequence 5′-GCU
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from Ambion (Austin, TX).
Cell viability assay
Cell viability was assessed 72 h post-infection using a (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) or (MTT)-
based assay (In Vitro Toxicology, Sigma-Aldrich, St. Loius, MO)
according to themanufacturer's instructions. To control for differences
in cell propagation rates, infected sample viability levels were
normalized by non-infected sample viability levels for the same
transfection. The normalized viability data for each transfected group
were compared to normalized viability data for non-targeting siRNA
transfection samples.
RAS activity assay
105 cells were plated in each well of 24-well plate in triplicates.
Cells were serum-starved for 5 h prior to lysis. Total protein was
determined by Bio-Rad Protein Assay (Bio-Rad, Hercules, CA). 25 μg of
whole-cell extracts was assayed for RAS activity using the RAS GTPase
Chemi ELISA Kit (Active Motif, Carlsbad, CA) according to the
manufacturer's instructions.
Transient transfection of plasmid DNA into HEK 293 cells
pcDNA3.1-HRAS-G12V and pcDNA3.1-HRAS-S17N plasmids
express 3×HA tagged (N-terminus) constitutively active RAS mutant
and dominant-negative RAS mutant, respectively (UMR cDNA
Resource Center, Rolla, MO). Parental vector pcDNA3.1+ was pur-
chased from Invitrogen (Carlsbad, CA). HEK 293 cells were maintained
in MEM-Eagle containing 2 mM glutamine, 0.1 mMMEM non-essential
amino acids, 1 mM sodium pyruvate, 1.5 g/l sodium bicarbonate, and
10% FBS (v/v). Transfection procedure was carried out according to the
manufacture's instructions (“Lipofectamine2000 Transfection Proce-
dure for DNA”, Invitrogen, Carlsbad, CA). Brieﬂy, 24 h before the
transfection 1×105 HEK 293 cells were seeded in each well of 24-well
plates. Transfections were carried out in triplicate using 2 μl of
Lipofectamine2000 reagent and 0.8 μg of plasmid per well in 1 ml of
medium. Plasmid–Lipofectamine2000 complexes were removed 4–6 h
after transfection.
Statistical analysis
To establish the statistical signiﬁcance of each comparison, two-
tailed Student's t-tests, assuming unequal variance, were performed.
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